4DMT reports Q2 net loss $35M, cash $578M; positive 4D-150 interim data; FDA lifts clinical hold on 4D-310

4D Molecular Therapeutics, Inc.

2024-Q2 EPS reported -$1.29 revenue$33,000

Cash and equivalents $578M as of June 30, 2024; expected to fund operations into H1 2027.
Q2 net loss $35.0M vs $29.6M YoY; R&D expenses rose to $31.9M from $23.6M.
Phase 2 PRISM 4D-150 in wet AMD: 89% reduction in annualized anti-VEGF injections; 77% injection-free at 24 weeks with 3E10 vg/eye dose.
FDA removed clinical hold on Phase 1/2 INGLAXA trial for 4D-310 in Fabry disease cardiomyopathy; enrollment to resume H2 2024.
Senior leadership added: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophth); Ophthalmology Advisory Board formed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.